NCT07468136 2026-04-13
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Mayo Clinic
Phase 1/2 Not yet recruiting
Clinical Trials
34 trialsNCT07520006 2026-04-13
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Nurix Therapeutics, Inc.
Phase 1/2 Not yet recruiting
NCT07519772 2026-04-09
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Merck Sharp & Dohme LLC
Phase 1/2 Not yet recruiting
NCT07225985 2026-04-03
Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma
Fred Hutchinson Cancer Center
Phase 1/2 Not yet recruiting
NCT07506668 2026-04-02
RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
Affiliated Hospital of Nantong University
Phase 1/2 Not yet recruiting
NCT07502768 2026-03-31
EpiRev-NKT
Fudan University
Phase 1/2 Not yet recruiting
NCT07503353 2026-03-31
A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies
Sheba Medical Center
Phase 1/2 Not yet recruiting
NCT07496229 2026-03-27
Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
Dizal Pharmaceuticals
Phase 1/2 Not yet recruiting
NCT07439653 2026-02-27
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
TORL Biotherapeutics, LLC
Phase 1/2 Not yet recruiting
NCT07283679 2026-02-24
Phase I/II Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Not yet recruiting
NCT07420959 2026-02-19
ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia
Mayo Clinic
Phase 1/2 Not yet recruiting
NCT07398638 2026-02-10
Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study
Sun Yat-sen University
Phase 1/2 Not yet recruiting
NCT07387926 2026-02-04
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Novartis
Phase 1/2 Not yet recruiting
NCT07339527 2026-01-14
EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas
Sun Yat-sen University
Phase 1/2 Not yet recruiting
NCT07333469 2026-01-13
A Clinical Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07311746 2025-12-31
Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Not yet recruiting
NCT07288814 2025-12-17
Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)
Sun Yat-sen University
Phase 1/2 Not yet recruiting
NCT07209163 2025-10-06
Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma
Ruijin Hospital
Phase 1/2 Not yet recruiting
NCT06979076 2025-09-29
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL
MingSight Pharmaceuticals, Inc
Phase 1/2 Not yet recruiting
NCT07107204 2025-09-17
A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies
Biotroy Therapeutics
Phase 1/2 Not yet recruiting
NCT07175415 2025-09-16
HEM-iSMART E
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Not yet recruiting
NCT07162571 2025-09-09
MSTH-CAR002
Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
Phase 1/2 Not yet recruiting
NCT07159906 2025-09-08
Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
First Affiliated Hospital of Zhejiang University
Phase 1/2 Not yet recruiting
NCT07035379 2025-08-22
A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL
Zhejiang Teruisi Pharmaceutical Inc.
Phase 1/2 Not yet recruiting
NCT07117305 2025-08-12
CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation
Zhengzhou University
Phase 1/2 Not yet recruiting
NCT06703216 2025-06-15
PACER
Ann & Robert H Lurie Children's Hospital of Chicago
Phase 1/2 Not yet recruiting
NCT07020260 2025-06-13
PACMAN
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Not yet recruiting
NCT06845241 2025-02-25
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2 Not yet recruiting
NCT06757387 2025-01-03
Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma
Peking University Cancer Hospital & Institute
Phase 1/2 Not yet recruiting
NCT06684509 2024-11-12
Atorvaststin and Cardiotoxicity in Acute Myloid Leukemia
Assiut University
Phase 1/2 Not yet recruiting
NCT05091541 2021-10-25
A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Nanjing IASO Biotechnology Co., Ltd.
Phase 1/2 Not yet recruiting
NCT05055791 2021-09-24
A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1/2 Not yet recruiting
NCT05054465 2021-09-23
ITALLI001
Israeli Medical Association
Phase 1/2 Not yet recruiting
NCT04856137 2021-04-23
DLBL
National Health Research Institutes, Taiwan
Phase 1/2 Not yet recruiting